Emcure Pharmaceuticals (NSE:EMCURE) ROCE % : 19.78% (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Emcure Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Emcure Pharmaceuticals's annualized ROCE % for the quarter that ended in Dec. 2024 was 19.78%.

Emcure Pharmaceuticals ROCE % Historical Data

The historical data trend for Emcure Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emcure Pharmaceuticals ROCE % Chart

Emcure Pharmaceuticals Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

ROCE %

29.29

34.90

27.81

23.18

Emcure Pharmaceuticals Quarterly Data
	Mar21	Mar22	Mar23	Sep23	Dec23	Mar24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial			27.44	24.14	19.50	25.86	19.78

Emcure Pharmaceuticals ROCE % Calculation

Emcure Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	9560.02	/	( ( (66725.31 - 30191.92)	+	(78061.63 - 32104.73) )	/ 2 )
	=	9560.02	/	( (36533.39	+	45956.9)	/ 2 )
	=	9560.02	/	41245.145
	=	23.18 %

Emcure Pharmaceuticals's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	10467.88	/	( ( (81244.78 - 28320.98)	+	(0 - 0) )	/ 1 )
	=	10467.88	/	( ( 52923.8	+	0 )	/ 1 )
	=	10467.88	/	52923.8
	=	19.78 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Emcure Pharmaceuticals (NSE:EMCURE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Emcure Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Emcure Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Emcure Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emcure Pharmaceuticals Ltd (NSE:EMCURE) » Definitions » ROCE %

Traded in Other Exchanges

544210:India

Address

Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Hinjawadi, MH, IND, 411057

Website

https://www.emcure.com

Emcure Pharmaceuticals Ltd an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several therapeutic areas. Its portfolio includes orals including solids, liquid orals and dry syrup/suspensions., injectables such as vials and pre-filled syringes, and forms such as lyophilized & liquid and biotherapeutics.

Emcure Pharmaceuticals Headlines

No Headlines